Roivant Sciences (ROIV) AI Stock Analysis

• Market Cap: $12.44B
• Dividend Yield: N/A
• Average Volume (3M): 8.49M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: -85.32%
• EPS Growth: -111.82%
• Country: US
• Employees: 908
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.25
• Shares Outstanding: 682,881,700
• 10 Day Avg. Volume: 8,108,491
• 30 Day Avg. Volume: 8,494,482
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 160.61
• Enterprise Value/Gross Profit: 177.70
• Enterprise Value/Ebitda: -3.80
• 1Y Price Target: $20.31
• Price Target Upside: 7.97% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 61 Neutral
• Price Target: $19.00 ▲(1.01% Upside)

Roivant Sciences' stock score is primarily influenced by its strong technical momentum and positive earnings call sentiment, despite significant financial challenges. The company's robust pipeline progress and strategic financial maneuvers provide optimism, but ongoing losses and litigation risks temper the overall outlook.

Positive Factors

Strong Financial Position

A strong cash position and no debt provide Roivant with significant financial flexibility to invest in R&D and strategic initiatives, supporting long-term growth.

Pipeline Progress

Advancements in the pipeline, especially in registrational trials, indicate potential future revenue streams and strengthen Roivant's competitive position in the biotech sector.

Promising Study Results

Promising results from Immunovant's study on Graves’ Disease suggest potential breakthroughs in treatment, enhancing Roivant's reputation and market potential in the biotech industry.

Negative Factors

Declining Revenue Growth

A sharp decline in revenue growth reflects challenges in monetizing products, which may hinder Roivant's ability to sustain operations and invest in future projects.

Negative Cash Flows

Negative cash flows indicate ongoing operational cash burn, which can strain resources and limit Roivant's capacity to fund future development and expansion efforts.

Ongoing Litigation

Litigation can be costly and time-consuming, potentially diverting resources away from R&D and strategic initiatives, impacting Roivant's long-term operational focus.

Roivant Sciences Business Overview & Revenue Model

Company Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

How the Company Makes Money

Roivant Sciences generates revenue primarily through the development and commercialization of pharmaceutical products. The company makes money from several key revenue streams, including milestone payments from collaborations with pharmaceutical companies, royalties on product sales from its subsidiaries, and potential revenues from licensing agreements. Roivant often partners with larger pharmaceutical companies to co-develop drugs, which can provide upfront payments and shared profits. Additionally, the company may receive funding from investors and venture capitalists to support its research and development activities, further contributing to its financial resources.

Roivant Sciences Financial Statement Overview

Summary

Roivant Sciences faces significant financial challenges, with declining revenues and persistent losses impacting profitability. While the company maintains a strong equity base and low leverage, its negative cash flows and profitability metrics highlight the need for strategic improvements.

Income Statement

Roivant Sciences shows significant volatility in its income statement metrics. The company has experienced a sharp decline in revenue growth, with a TTM revenue growth rate of -69.51%. Profitability metrics are concerning, with negative net profit and EBIT margins, indicating ongoing losses. The gross profit margin remains high at 92.05% TTM, suggesting efficient cost management, but overall profitability is severely impacted by high operating expenses.

Balance Sheet

The balance sheet reflects a relatively stable financial position with a low debt-to-equity ratio of 0.021 TTM, indicating low leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly provided, but the company's substantial equity base suggests a strong capital structure. Despite low leverage, the negative ROE highlights profitability challenges.

Cash Flow

Cash flow analysis reveals challenges with negative operating cash flow and free cash flow. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is somewhat aligned with net income, albeit both are negative. The free cash flow growth rate is positive at 1.73% TTM, but the overall cash flow position remains weak, reflecting ongoing operational cash burn.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.23M	29.05M	124.80M	61.28M	55.29M	23.80M
Gross Profit	21.00M	28.14M	96.83M	48.15M	46.32M	21.74M
EBITDA	-981.34M	-674.26M	4.31B	-1.18B	-916.71M	-895.74M
Net Income	-490.63M	-171.98M	4.35B	-1.01B	-845.26M	-809.23M
Balance Sheet
Total Assets	5.03B	5.44B	7.22B	2.39B	2.59B	2.69B
Cash, Cash Equivalents and Short-Term Investments	4.50B	4.89B	6.54B	1.68B	2.06B	2.13B
Total Debt	99.69M	100.17M	499.75M	481.40M	283.89M	244.98M
Total Liabilities	216.70M	249.74M	773.95M	782.02M	523.70M	527.69M
Stockholders Equity	4.35B	4.69B	5.97B	1.16B	1.66B	1.80B
Cash Flow
Free Cash Flow	-858.67M	-844.05M	-766.65M	-856.08M	-695.16M	-557.94M
Operating Cash Flow	-851.00M	-839.45M	-765.27M	-843.39M	-677.73M	-552.14M
Investing Cash Flow	-2.85B	-1.77B	5.20B	-44.27M	303.30M	-31.70M
Financing Cash Flow	-746.95M	-1.22B	419.36M	499.46M	306.79M	456.26M

Roivant Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ROIV, the sentiment is Positive. The current price of 18.81 is above the 20-day moving average (MA) of 16.81, above the 50-day MA of 14.74, and above the 200-day MA of 11.88, indicating a bullish trend. The MACD of 1.03 indicates Negative momentum. The RSI at 90.07 is Negative, neither overbought nor oversold. The STOCH value of 92.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ROIV.

Roivant Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	―	$7.74B	15.04	179.14%	―	34.97%	71.10%
TECH	―	$10.26B	143.49	3.68%	0.50%	5.23%	-56.70%
CORT	―	$7.64B	64.57	21.42%	―	25.71%	4.48%
VRNA	―	―	―	―	―	―	34.29%
JAZZ	―	$8.40B	―	-10.84%	―	4.52%	-205.13%
ROIV	―	$12.44B	―	-15.84%	―	-85.32%	-111.82%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Roivant Sciences Corporate Events

Roivant Sciences Announces Positive Phase 3 Study Results

On September 17, 2025, Roivant Sciences announced positive results from the Phase 3 VALOR study of brepocitinib in dermatomyositis, marking the first successful 52-week placebo-controlled trial for this condition. The study demonstrated significant improvements in patients, with brepocitinib showing a clinically meaningful response compared to placebo on both primary and secondary endpoints, and a consistent safety profile. This breakthrough positions brepocitinib as a potential impactful treatment option for dermatomyositis, with an NDA filing planned for the first half of 2026.

The most recent analyst rating on (ROIV) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.

Roivant Sciences Approves Proposals at Annual Meeting

On September 10, 2025, Roivant Sciences Ltd. held its Annual General Meeting of Shareholders, where all proposals on the agenda were approved. These included the re-election of Class I directors, the ratification of Ernst & Young LLP as the independent auditor, and a non-binding advisory vote on executive compensation. The meeting saw participation from holders of 628,673,675 common shares, reflecting strong shareholder engagement. The approval of these proposals is expected to reinforce Roivant’s governance structure and operational transparency, potentially enhancing its position in the biopharmaceutical industry.

The most recent analyst rating on (ROIV) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.

Roivant Sciences Announces Promising Study Results

On September 3, 2025, Roivant Sciences announced promising results from a proof-of-concept study conducted by its subsidiary, Immunovant, on the treatment of uncontrolled Graves’ Disease using batoclimab. The study revealed that approximately 80% of patients maintained normal thyroid function six months after treatment, with around 50% achieving remission without anti-thyroid drugs. These findings suggest a potential shift in the treatment paradigm for Graves’ Disease, with two registrational trials for IMVT-1402 currently enrolling and results expected in 2027.

The most recent analyst rating on (ROIV) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.

Roivant Sciences Earnings Call: Progress Amid Challenges

Roivant Sciences Ltd. recently held its earnings call, showcasing a blend of optimism and challenges. The company expressed confidence in its drug development progress and robust financial standing, despite facing litigation hurdles and rising costs. Roivant remains hopeful about future product launches and favorable litigation outcomes.

Roivant Sciences Reports Q1 2025 Financial Results

Roivant Sciences Ltd. is a biopharmaceutical company focused on accelerating the development and commercialization of innovative medicines across various therapeutic areas, including autoimmune diseases and pulmonary hypertension. In its latest earnings report for the first quarter ended June 30, 2025, Roivant highlighted significant clinical progress and strategic financial maneuvers. The company completed a $1.5 billion share repurchase program and initiated a new $500 million buyback, reflecting its commitment to shareholder value. Additionally, Roivant reported consolidated cash and marketable securities of $4.5 billion, supporting its financial stability and future growth.